BrightGene Bio Medical Technology C (688166) — Tangible Net Worth Ratio
BrightGene Bio Medical Technology C (688166) has a Tangible Net Worth Ratio of 88.0% as of June 2025. This metric is calculated by deducting intangible assets (CN¥311.28 Million) from net assets (CN¥2.59 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See BrightGene Bio Medical Technology C (688166) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
BrightGene Bio Medical Technology C Tangible Net Worth Ratio (2016–2024)
This chart shows how BrightGene Bio Medical Technology C's Tangible Net Worth Ratio has changed across 9 annual periods from 2016 to 2024. As of June 2025, the ratio stands at 88.0%, reflecting net assets of CN¥2.59 Billion with intangible assets of CN¥311.28 Million CNY. See operational self-sufficiency of BrightGene Bio Medical Technology C to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for BrightGene Bio Medical Technology C (2016–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for BrightGene Bio Medical Technology C from 2016 to 2024, covering 9 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see BrightGene Bio Medical Technology C (688166) market capitalisation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 95.7% | CN¥2.44 Billion | CN¥103.82 Million | CN¥5.16 Billion | ▼ -0.4 pp |
| 2023 | 96.1% | CN¥2.42 Billion | CN¥93.66 Million | CN¥5.03 Billion | ▼ -0.2 pp |
| 2022 | 96.4% | CN¥2.24 Billion | CN¥81.64 Million | CN¥4.66 Billion | ▲ +1.0 pp |
| 2021 | 95.4% | CN¥1.74 Billion | CN¥80.84 Million | CN¥2.97 Billion | ▼ -1.2 pp |
| 2020 | 96.6% | CN¥1.43 Billion | CN¥48.76 Million | CN¥1.83 Billion | ▼ -3.0 pp |
| 2019 | 99.6% | CN¥1.31 Billion | CN¥5.81 Million | CN¥1.42 Billion | ▲ +0.2 pp |
| 2018 | 99.3% | CN¥772.85 Million | CN¥5.05 Million | CN¥878.37 Million | ▲ +1.2 pp |
| 2017 | 98.1% | CN¥446.02 Million | CN¥8.31 Million | CN¥524.92 Million | ▲ +1.9 pp |
| 2016 | 96.3% | CN¥220.15 Million | CN¥8.18 Million | CN¥384.19 Million | — |